Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize

®

antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5089985. A live audio webcast of the call will also be available on the Presentations section of the Company’s website,

www.biopathholdings.com

. An archived webcast will be available on the Bio-Path website approximately two hours after the event.



About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize

®

, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022.

For more information, please visit the Company’s website at

Home



.



Contact Information:



Investors

Will O’Connor

Stern Investor Relations

212-362-1200


[email protected]

Doug Morris

Investor Relations

Bio-Path Holdings, Inc.

832-742-1369


Primary Logo